| --- | --- | --- | --- | |----------------|------------------------------------------------------|-------|-------------------------------------------------| | | | | | | | Advancing Life-Changing Discoveries in Neuroscience | | Q3 2020 Corporate Presentation November 9, 2020 | | neurocrine.com | | | Nasdaq: NBIX | Safe Harbor Statement and Non-GAAP Financial Measures In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertainties. These ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q3 2020 Earnings Conference Call November 9, 2020 4:30 PM ET Company Participants Todd Tushla - Vice President, Investor Relations Kevin Gorman - Chief Executive Officer Matthew Abernethy - Chief Financial Officer Eric Benevich - Chief Commercial Officer Eiry Roberts - Chief Medical Officer Conference Call Participants Josh Schimmer - Evercore ISI Tazeen Ahmad - Bank of America Paul Matteis - Stifel Biren Amin - Jefferies Phil Nadeau - Cowen & Company Brian Skorney ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-22705 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

Neurocrine® Advancing Life-Changing Discoveries in Neuroscience Q2 2020 Corporate Presentation August 3, 2020 Nasdaq: NBIX neurocrine.com Safe Harbor Statement and Non-GAAP Financial Measures In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to: the benefits to be derived from our products and product candidates; the value our products and/or our product ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q2 2020 Results Conference Call August 3, 2020 4:30 PM ET Company Participants Todd Tushla - VP, IR Kevin Gorman - CEO Matt Abernethy - CFO Eiry Roberts - Chief Medical Officer Eric Benevich - Chief Commercial Officer Kyle Gano - Chief Business Development and Strategy Officer Conference Call Participants Paul Matteis - Stifel Phil Nadeau - Cowen and Company Brian Abrahams - RBC David Amsellem - Piper Sandler Paul Choi - Goldman Sachs Marc Goodman - SVB Leerink Bir ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-22705 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of ...

Neurocrine® Advancing Life-Changing Discoveries in Neuroscience Q1 2020 Corporate Presentation May 6, 2020 Nasdaq: NBIX neurocrine.com Safe Harbor Statement and Non-GAAP Financial Measures In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to: the benefits to be derived from our products and product candidates, including INGREZZA, ONGENTYS, and our partne ...

Neurocrine Bioscineces, Inc. (NASDAQ:NBIX) Q1 2020 Earnings Conference Call May 6, 2020 4:30 PM ET Company Participants Kevin Gorman ??? Chief Executive Officer Todd Tushla ??? Head-Investor Relations Matt Abernethy ??? Chief Financial Officer Eric Benevich ??? Chief Commercial Officer Eiry Roberts ??? Chief Medical Officer Kyle Gano ??? Chief Business Development Officer Conference Call Participants Paul Matteis ??? Stifel Biren Amin ??? Jefferies LLC Jack Allen ??? Baird Anupam Rama ??? JPMorgan Jay Olsen ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-Q Washington, D.C. 20549 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR 12780 El Camino Real, San Diego, California 92130 (Address of principal executive office) (Zip Code) (IRS Employer Identification No.) (858) 617-7600 (Registrant's telephone number, including area code) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANG ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Commission file number 0-22705 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 33-0525145 (State or other jurisdiction of incorporation or organization) 12780 El Camino Real, San Diego, California 92130 (Address of principal executive offices) (Zip Code) (858) 617-7600 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Co ...